Absorption Systems announced the results of another study demonstrating the power of the company’s CellPort Technologies to predict the potential for pharmacokinetic drug-drug interactions.
The ProteaseArrest family of protease inhibitor cocktails are unique ready-to-use liquid format cocktails that offer immediate >98% inhibition of harmful proteases.
AMSBIO has announced the launch of Alvetex, a cell culture scaffold that enables genuine 3D cell culture to be grown routinely and cost-effectively.
Merck and Sanofi Pasteur announced the initiation of a Phase 3 clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.
Clinical-stage drugmaker Pharmasset Inc. reported a wider fiscal second-quarter loss Monday on higher research and development costs. The company lost $19.9 million, or 55 cents per share, in the quarter ended March 31.
An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.
A new immunological technique, in which patients are infected with malaria at the same time as being treated with prophylactic chloroquinine drugs, can give immunity against re-infection for at least 2.5 years, much longer than for immunity acquired naturally.
Generic drugmaker Mylan Inc. said it has launched a generic version of Novartis' breast cancer treatment Femara. Mylan and Novartis settled a patent dispute over the drug in 2008.
The U.S. Food and Drug Administration approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Federal health officials said a highly-anticipated drug to treat hepatitis C made by Merck appears to cure more patients in less time than established drugs that have been used for 20 years.
Pozen Inc. said that it filed a patent infringement lawsuit against generic drugmaker Dr. Reddy's Laboratories Ltd., which is seeking approval for a generic version of its osteoarthritis drug Vimovo.
Researchers have discovered a compound called L-BHDA that has the potential to be more effective than existing agents in treating the very painful blisters known as shingles.
Researchers have published promising results of a clinical study using pirfenidone, an experimental anti-fibrotic and anti-inflammatory drug, to treat patients with diabetic nephropathy.
UCLA researchers have demonstrated the ability to package drug-loaded "nanodisks" into naturally occurring nanoscale capsules that have been engineered for therapeutic drug delivery.